Extended use for Remicade in Crohn's disease

Coloured X-ray of the intestine in Crohn’s disease | SCIENCE PHOTO LIBRARY
Coloured X-ray of the intestine in Crohn’s disease | SCIENCE PHOTO LIBRARY

Approval for the use of Remicade (infliximab) in Crohn’s disease has been extended to include moderately active disease.

The licence extension is based on the results of the double-blind SONIC study. Investigators randomised 508 adults with moderate to severe Crohn’s disease to receive infliximab, azathioprine, or infliximab plus azathioprine.

After 26 weeks, the rate of corticosteroid-free clinical remission was higher among the patients who received infliximab (44.4%) or combination therapy (56.8%) than among those who were given azathioprine only (30.0%; p=0.006 and p<0.001, respectively). Rates of mucosal healing were also significantly greater in the 2 infliximab groups than in the azathioprine-only group.

Dosing of infliximab in moderate Crohn’s disease is the same as for severe disease.

View Remicade drug record

Further Information: Schering-Plough

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more